ADC Therapeutics Reports Strong Preliminary FY25 Revenue, $261M Cash, and Extends Runway to 2028 with Positive Clinical Updates

summarizeSummary

ADC Therapeutics announced preliminary Q4 and full-year 2025 revenue, a robust cash position of $261 million, and an extended cash runway through at least 2028, alongside positive updates from its ZYNLONTA clinical programs.

check_boxKey Events

• Strong Cash Position & Runway

  Reported preliminary cash and cash equivalents of approximately $261 million as of December 31, 2025, which is expected to extend the cash runway through at least 2028.

• Preliminary FY25 Revenue

  Announced preliminary unaudited full-year 2025 ZYNLONTA net product revenue of approximately $73 million, an increase from $69.3 million in 2024.

• Positive LOTIS-7 Clinical Data

  Updated data from the LOTIS-7 trial demonstrated an 89.8% overall response rate and a 77.6% complete response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

• Key Clinical Milestones Ahead

  Anticipates topline data from the LOTIS-5 Phase 3 trial in Q2 2026 and full LOTIS-7 results by the end of 2026, with potential regulatory approvals and compendia inclusions to follow.

auto_awesomeAnalysis

This 8-K filing provides a highly positive update for ADC Therapeutics, primarily driven by its strong financial position and extended cash runway. The company's preliminary cash and cash equivalents of $261 million as of December 31, 2025, are expected to fund operations through at least 2028, significantly de-risking the company's financial outlook and providing ample time for its clinical pipeline to mature. While preliminary full-year 2025 ZYNLONTA revenue of $73 million shows modest growth, the company anticipates an acceleration in revenue growth starting in 2027, contingent on positive clinical trial outcomes. Key upcoming catalysts include topline data from the LOTIS-5 Phase 3 trial in Q2 2026 and full data from LOTIS-7 by the end of 2026, both of which could expand ZYNLONTA's market indications and drive future sales. The strong cash position and clear clinical development path are critical for investor confidence in this life sciences company.